Roger Kamba & Gilead Sciences

Roger Kamba: Roger Kamba, the Congolese Health Minister, confirmed the Bundibugyo ebolavirus strain in the Ebola outbreak and highlighted its high lethality rate and the lack of a specific vaccine or treatment for this variant.

Gilead Sciences: Gilead Sciences is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

Roger Kamba: Roger Kamba>>>, the Congolese health minister, has been actively involved in the response, announcing the opening of treatment centers and acknowledging the challenges in containing the outbreak.

Gilead Sciences: Gilead Sciences' antiviral drug remdesivir and experimental drug obeldesivir are being prioritized for clinical trials to treat or prevent the Bundibugyo ebolavirus, indicating its significant role in potential therapies.

Roger Kamba: Congo's Health Minister Roger Kamba has discussed exploring more drugs and compounds to save lives from the Bundibugyo virus, acknowledging its initial presentation similar to other infectious diseases.

Gilead Sciences: Gilead Sciences' experimental oral COVID antiviral drug, Obeldesivir, is being considered for use as a preventative treatment for Ebola contacts, under strict protocol.